慢性鼻窦炎的局部糖皮质激素冲洗治疗
本文通过聚焦文献综述纳入2013至2018年11篇原创文章,评估局部糖皮质激素冲洗治疗慢性鼻窦炎(CRS)的疗效与安全性。综述指出,局部糖皮质激素冲洗在术后CRS患者中应被视为一线药物治疗的一部分,长期每日使用不增加眼压升高、下丘脑-垂体-肾上腺轴抑制或后囊下白内障风险。
要点
- 局部糖皮质激素冲洗在术后CRS患者中应被视为一线药物治疗的一部分。
- 长期每日使用局部糖皮质激素不增加眼压升高、下丘脑-垂体-肾上腺轴抑制或后囊下白内障风险。
- 治疗范式应包括广泛而完整的内镜鼻窦手术,以充分递送局部治疗。
核心结论
- 局部糖皮质激素冲洗应被视为术后CRS患者一线药物治疗的一部分。
- 长期每日使用局部糖皮质激素不增加眼压升高、下丘脑-垂体-肾上腺轴抑制或后囊下白内障风险,尽管存在一定的全身吸收。
研究设计与样本
- 聚焦文献综述,纳入2013至2018年间评估局部糖皮质激素冲洗安全性或疗效的11篇原创文章。
主要发现
- 一项研究发现糖皮质激素冲洗相比糖皮质激素喷雾有显著获益。
- 两项研究发现糖皮质激素冲洗相比生理盐水冲洗有显著获益,而另两项研究未发现。
- 一项研究发现糖皮质激素冲洗相比不冲洗在特定患者人群中显著改善。
- 五项研究发现使用局部糖皮质激素未显著增加不良副作用风险。
临床怎么用
- 治疗范式应包括广泛而完整的内镜鼻窦手术,以充分递送局部治疗。
- 局部治疗应使用大容量、低压力装置,并给予足够剂量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) has previously been thought to occur secondary to infectious or obstructive etiologies. However, in recent years, primary CRS has been more discretely defined as diffuse airway inflammation, similar to asthma. Adequate medical and surgical therapy are needed to control the inflammation. Our purpose in this study was to evaluate the efficacy and safety of topical corticosteroid treatment. METHODS: A focused literature review was conducted and we identified 11 original articles from the years 2013-2018 evaluating safety or efficacy of topical corticosteroid irrigations. RESULTS: Eleven articles were identified. One study found significant benefit between corticosteroid irrigations versus corticosteroid sprays. Two studies found significant benefit between corticosteroid irrigations compared to saline irrigations while two did not. One study found significant improvement in certain patient populations when using corticosteroid irrigations compared to no irrigation. Five studies found no significant increase in risk of adverse side effects with the use of topical corticosteroids. CONCLUSION: Many factors are associated with efficacious and adequate treatment of primary CRS. The pathology must be correctly diagnosed and be inflammatory in nature. The treatment paradigm should include wide and complete endoscopic sinus surgery for the adequate delivery of topical therapy. Topical therapy should be delivered in large-volume, low-pressure devices with adequate dosing. Although there is some systemic absorption, multiple studies have demonstrated that long-term, daily use of topical corticosteroids does not increase intraocular pressure, suppress the hypothalamic-pituitary-adrenal axis, or increase the risk of subcapsular cataracts. Therefore, topical corticosteroid irrigations should be considered a part of first-line medical treatment in postsurgical CRS patients.
引用
- Grayson JW, Harvey RJ. Topical corticosteroid irrigations in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019. PMID: 31087637. doi:10.1002/alr.22331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。